One and Two-Year Persistence with Different Anti-Osteoporosis Medications

Primary tabs

SCIENCE
One and Two-Year Persistence with Different Anti-Osteoporosis Medications
Key Take-Away: 

Osteoporotic fractures are one of the major causes of increased morbidity and mortality.

The risk of future fractures is further escalated with the previous fractures. This increased risk can be reduced by using anti-osteoporosis medications. In this study, persistence time of different types of anti-osteoporosis drugs have been compared, and it has been concluded that teriparatide and denosumab exhibit better persistence levels than alendronate.

The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications.

ABSTRACT: 
Background: 

The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications.

Methods: 

This is a retrospective cohort using data from anonymised records and dispensation data. Eligibility comprised the following: women aged ≥50, incident users of anti-osteoporosis medication (2012), with data available for at least 12 months prior to therapy initiation.

Exclusions are other bone diseases/treatments and uncommon anti-osteoporosis drugs (N < 100). Follow-up was from first pharmacy dispensation until cessation, end of study, censoring or switching. Outcomes are 2- and 1-year persistence with a permissible gap of up to 90 days. Persistence with alendronate was compared to other bisphosphonates, strontium ranelate, selective oestrogen receptor modulators, teriparatide, and denosumab. Cox models were used to estimate hazard ratios of therapy cessation according to the drug used after adjustment for age, sex, BMI, smoking, alcohol drinking, Charlson co-morbidity index, previous fractures, use of anti-osteoporosis medication/s, oral corticosteroids and socio-economic status.

Results: 

A total of 19,253 women were included. Unadjusted 2-year persistence [95% CI] ranged from 10.3% [9.1-11.6%] (strontium ranelate) to 45.4% [43.1-47.8%] (denosumab). One-year persistence went from 35.8% [33.9%-37.7%] (strontium ranelate) to 65.8% [63.6%-68.0%] (denosumab).

At the end of the first year and compared to alendronate users, both teriparatide and denosumab users had reduced cessation risk (adjusted HR 0.76, 95% CI 0.67-0.86 and 0.54, 95% CI 0.50-0.59 respectively) while at the end of the second year, only denosumab had a lower risk of discontinuation (adjusted HR 0.60, 95% CI 0.56-0.64).

Conclusion: 

Unadjusted 2-year persistence is suboptimal. However, both teriparatide and denosumab users had better 1-year, and only denosumab had 2-year better persistence compared to alendronate users. Unmeasured confounding by indication might partially explain our findings.

 

Source:

Osteoporos Int. 2017 Jul 16

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/28714038#

The original title of the article:

One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.

Authors:

Reyes C et al.

Therapeutic, Alendronate, Denosumab, Teriparatide, Strontium Ranelate, Osteoporosis, Bones, Bisphosphonates, Monoclonal Antibody, Recombinant Parathyroid Hormone, Antiosteoporotic Agent, Retrospective Cohort Study, Persistence
Log in or register to post comments